|本期目录/Table of Contents|

[1]王小敏,王文静,许俊翱,等.儿科门诊应用微生态制剂的合理性与安全性分析[J].医学研究与战创伤救治(原医学研究生学报),2023,25(3):280-285.[doi:10.3969/j.issn.1672-271X.2023.03.012]
　WANG Xiaomin,WANG Wenjing,XU Junao,et al.Rationality and safety analysis of probioties in pediatric outpatient applications[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2023,25(3):280-285.[doi:10.3969/j.issn.1672-271X.2023.03.012]
点击复制

儿科门诊应用微生态制剂的合理性与安全性分析()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第25卷
期数:
2023年3期
页码:
280-285
栏目:
药学研究
出版日期:
2023-08-01

文章信息/Info

Title:
Rationality and safety analysis of probioties in pediatric outpatient applications
作者:
王小敏; 王文静; 许俊翱; 柳仁凤
作者单位：215006苏州，苏州大学附属儿童医院药剂科（王小敏、王文静、柳仁凤）；215007 苏州，苏州市第五人民医院药剂科（许俊翱）
Author(s):
WANG Xiaomin1;  WANG Wenjing1;  XU Jun’ao2;  LIU Renfeng1
(1.Pharmacy Department, the Children’s Hospital of Soochow University, Soochow 215006，Jiangsu,China; 2.Pharmacy Department, the Fifth People’s Hospital of Soochow, Soochow 215007，Jiangsu,China）
关键词:
微生态制剂; 处方分析; 儿科门诊; 合理性
Keywords:
probioties; prescription analysis; pediatric clinic; rationality
分类号:
R969.3
DOI:
10.3969/j.issn.1672-271X.2023.03.012
文献标志码:
A
摘要:
目的了解医院微生态制剂临床应用合理性与安全性现状，为儿童合理应用提供参考。方法通过医院信息系统，检索2022年1-12月苏州大学附属儿童医院含微生态制剂的门诊处方，并根据处方审核建议进行分析。结果共筛选出含微生态制剂的处方236 604 张，包含酪酸梭菌二联活菌散等7 种微生态制剂。其中，超适应证用药处方共61 549张，占26.01%；非常规剂量用药处方共103 666张，占46.94%，其中剂量过大处方数占81.10%，剂量不足处方数仅占18.90%；复方嗜酸乳杆菌片及酪酸梭菌二联活菌胶囊为幼儿期群体开具的处方有2084张，占总处方数的0.88%；临床应用中有重复用药的情况，但处方数所占比例不足1%。结论微生态制剂在儿童中超适应证用药的发生率较高，用药有循证医学证据均较低。用药规范程度有待提升，无论是在用药剂量还是用药剂型的选择上。微生态制剂在儿童疾病的扩大应用研究需更多更可靠的研究证据，且应尽可能规范处方行为，促进合理用药。
Abstract:
ObjectiveTo investigate the rationality and safety status of clinical application of probioties in our hospital, and to provide reference for the rational application of children.MethodsThe outpatient and emergency prescriptions containing probioties in our hospital during January to December 2022 were enrolled through the hospital information system, and analyzed according to the prescription review recommendations.ResultsA total of 236 604 prescriptions containing probioties were screened, including 7 kinds of probioties such as Combined Clostridium Butyricum and Bifidobacterium Powders. Among them, there were 61 549 out-of-indication drug prescriptions, accounting for 26.01%. There were 103 666 non-conventional dose prescriptions, accounting for 46.94%, among which over-dose prescriptions accounted for 81.10% and under-dose prescriptions only accounted for 18.90%. There were 2084 prescriptions of Compound Eosinophil-Lactobacillus Tablets and Combined Clostridium Butyricum and Bifidobacterium Capsules were prescribed for infants, accounting for 0.88% of the total prescriptions. There were cases of repeated drug use in clinical application, but the proportion of prescription was less than 1%.ConclusionThe incidence of out-of-indication drug use of probioties in children is high, and the evidence-based medical evidence for medication is low. The degree of medication standardization needs to be improved, whether in the choice of medication dose or dosage form. Further reliable research evidence is needed for the expansion of probioties in childhood diseases, and the prescribing behavior should be standardized as much as possible to promote rational drug use.

参考文献/References:

[1]Sotoudegan F, Daniali M, Hassani S, et al. Reappraisal of probiotics’ safety in human [J]. Food Chem Toxicol, 2019, 129:22-29.
[2]中华预防医学会微生态学分会. 中国微生态调节剂临床应用专家共识(2020版) [J]. 中国微生态学杂志. 2020,32(8):953-965.
[3]魏婷, 李燕, 蔡和平, 等. 微生态制剂儿科处方审核建议 [J]. 中国实用儿科杂志, 2022, 37(6):415-423.
[4]张惠玲, 董大伟, 邓本勇. 24992张儿童益生菌处方用药及超说明书用药情况分析 [J]. 中国医院用药评价与分析, 2019, 19(5): 609-611，615.
[5]Bravo D, Hoare A, Soto C, et al. Helicobacter pylori in human health and disease: Mechanisms for local gastric and systemic effects [J]. World J Gastroenterol, 2018，24(28): 3071-3089.
[6]刘俊莹, 李文辉, 贾莉, 等. 三联疗法联合益生菌对幽门螺杆菌感染患儿的临床疗效及对患儿生长发育的影响 [J]. 中国医药, 2022, 17(1):76-79.
[7]Shi XG, Zhang JH, Mo LS, et al. Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis [J]. Medicine (Baltimore), 2019，98(15): e15180.
[8]中华预防医学会微生态学分会. 中国微生态调节剂临床应用专家共识(2020版) [J]. 中国微生态学杂志, 2020, 32(8):953-965.
[9]中华医学会儿科学分会, 中华儿科杂志编辑委员会．儿童过敏性疾病诊断及治疗专家共识 [J]．中华儿科杂志, 2019, 57 (3) :164-171.
[10]王晶，郭城，张琳. 生命早期益生菌干预预防儿童过敏性疾病的Meta分析 [J]. 中国微生态学杂志, 2022, 34(2)：139-149.
[11]刘夏, 侯彬彬. 益生菌治疗过敏性疾病机制及应用的研究进展 [J]. 实用医学杂志, 2022, 38(11):1434-1438.
[12]Gehrig JL, Venkatesh S, Chang HW, et al. Effects of microbiota-directed foods in gnotobiotic animals and undernourished children [J]. Science,2019，365(6449).doi: 10.1126/science.aau4732.
[13]夏天一, 陈孟莉. 处方前置审核系统上线实践与应用研究展望 [J]. 东南国防医药，2022,24(4): 403-407.
[14]陈醒, 袁力, 王楠. 医院门诊处方前置审核的实施效果初探 [J]. 东南国防医药，2020, 22(5): 541-543.
[15]李帅, 薛进, 杜娆. 处方前置审核系统在某“三甲”儿童医院门急诊抗菌药物精细化管理中的应用与实践 [J]. 抗感染药学，2022, 19(7): 1075-1080.
[16]罗雨希, 刘丽. 肠道菌群对儿童急性白血病影响的研究进展 [J]. 医学研究生学报，2022, 35(9): 1004-1008.

相似文献/References:

[1]骆雨璇,陈醒,吴勤研,等.医保不合理用药处方分析与对策探讨[J].医学研究与战创伤救治(原医学研究生学报),2017,19(06):656.[doi:10.3969/j.issn.1672-271X.2017.06.025]

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2023-08-24